YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Major earnings expected before the bell on Thursday include: * AngioDynamics (ANGO [https://seekingalpha.com/symbol/ANGO]) * Byrna Technologies (BYRN [https://seekingalpha.com/symbol/BYRN]) * Helen of Troy Limited (HELE [https://seekingalp…
* AngioDynamics (ANGO [https://seekingalpha.com/symbol/ANGO]) said [https://seekingalpha.com/pr/20679088-angiodynamics-announces-appointment-of-eric-honroth-as-president-and-chief-executive-officer]Eric Honroth will become president and ch…
[Young blond female manager explaining quarterly results on large led screen] NicolasMcComber The first full week of October, though light, brings a diverse earnings slate spanning consumer staples, beverages, travel, apparel, and AI infra…
Despite accelerating revenue growth, Delta stock is struggling to reclaim its 50-day line ahead of its Q3 earnings report. Continue Reading
A month has gone by since the last earnings report for AngioDynamics (ANGO). Shares have added about 8.9% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading up…
Key Points Interested in AngioDynamics, Inc.? Here are five stocks we like better. MedTech is expected to become AngioDynamics' majority revenue source in fiscal 2027, rising from 47% of fiscal 2026 revenue. Management forecasts 12%–15% Me…
AngioDynamics, Inc. ANGO offers investors a clear trade-off. Its Med Tech platforms are expanding quickly, but near-term earnings conversion remains weak as tariffs and operating costs absorb part of the benefit. The investment case depend…
AngioDynamics, Inc. ANGO has set an initial fiscal 2027 framework that keeps its Med Tech transformation at the center of the investment case. Faster growth from its priority platforms is expected to lift sales, but margin pressure and con…
AngioDynamics, Inc. ANGO shares have gained 33.5% in the past three months, sharply outpacing the broader market and the medical sector. The rally reflects growing interest in the company's shift toward faster-growing Med Tech platforms. T…
(RTTNews) - The following biotech stocks reached a 52-week high on August 3, 2026, driven by key catalysts such as upcoming quarterly reports or the initiation of clinical trials. AngioDynamics Inc. (ANGO) AngioDynamics, a medical technolo…
Image source: The Motley Fool. DATE Tuesday, July 14, 2026 at 8:00 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Jim Clemmer Executive Vice President and Chief Financial Officer - Steve Trowbridge Full Conference Call T…
Image source: The Motley Fool. DATE Tuesday, July 14, 2026 at 8:00 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Jim ClemmerExecutive Vice President and Chief Financial Officer - Steve Trowbridge TAKEAWAYS Total Net Sal…
AngioDynamics, Inc. ANGO reported an adjusted loss per share of 7 cents for fourth-quarter fiscal 2026, wider than the year-ago quarter's adjusted loss of 3 cents but narrower than the Zacks Consensus Estimate of a loss of 11 cents. On a p…
Earnings Call Insights: AngioDynamics (ANGO) Q4 FY 2026 MANAGEMENT VIEW * "We capped off a year of consistent execution across the business with a strong fourth quarter. Full-year Med Tech growth of more than 18% tells the story." (CEO, Pr…
September S&P 500 E-Mini futures (ESU26) are down -0.06% this morning as investors digest earnings reports from big U.S. banks, with the focus now turning to key U.S. inflation data and Federal Reserve Chairman Kevin Warsh's congressional…
Major earnings expected before the bell on Tuesday include: * Bank of America Corporation (BAC [https://seekingalpha.com/symbol/BAC]) * JPMorgan Chase & Co. (JPM [https://seekingalpha.com/symbol/JPM]) * Citigroup (C [https://seekingalpha.c…
AngioDynamics ANGO has been gaining from its solid prospects with NanoKnife and an increased focus on cancer treatment markets. The optimism, led by a solid third-quarter fiscal 2026 performance, positive ongoing studies and a broad produc…
AngioDynamics ANGO recently announced that the FDA has approved its IDE application to initiate the RELIEF study, which will evaluate the irreversible electroporation (IRE) technology delivered by the company's NanoKnife System. The IRE wi…
(RTTNews) - AngioDynamics Inc. (ANGO), a medical technology company, on Wednesday reported that the U.S. Food and Drug Administration (FDA) approved an investigational device exemption (IDE) application, enabling the RELIEF study for the c…
Thermo Fisher Scientific TMO shares ended the last trading session 6.8% higher at $487.22. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 2.2% l…
AngioDynamics ANGO has been gaining from its solid prospects with NanoKnife and an increased focus on cancer treatment markets. The optimism, led by a solid third-quarter fiscal 2026 performance, positive ongoing studies and a broad produc…
AngioDynamics logo Key Points AngioDynamics completed a multi-year strategic reset with divestitures and innovation that left the company with no debt, significant cash and a revolver, while its MedTech segment has grown at a ~25% CAGR to…
AngioDynamics, Inc. ANGO reported an adjusted loss per share of 7 cents for third-quarter fiscal 2026, narrower than the year-ago quarter’s adjusted loss per share of 8 cents and the Zacks Consensus Estimate of a loss of 11 cents. GAAP los…
AngioDynamics, Inc. Q3 2026 Earnings Call Summary - Moby Strategic Execution and Portfolio Shift Performance was driven by a deliberate shift toward high-margin Med Tech markets, which now comprise 48% of total revenue compared to 44% in t…
The S&P 500 Index ($SPX) (SPY) today is down -1.13%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -1.15%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -1.53%. June E-mini S&P futures (ESM26) are down -1.07%, and June E-mini Nas…
The S&P 500 Index ($SPX) (SPY) today is down -0.06%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.23%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.20%. June E-mini S&P futures (ESM26) are down -0.04%, and June E-mini Nas…
Earnings Call Insights: AngioDynamics (ANGO) Q3 FY2026 MANAGEMENT VIEW * “Our third quarter was strong across the board,” James Clemmer said, adding that results were “led by impressive growth in our Med Tech segment” and that the company…
AngioDynamics logo AngioDynamics (NASDAQ:ANGO) reported fiscal 2026 third-quarter results that management described as “strong across the board,” highlighted by faster growth in its MedTech segment and improved adjusted EBITDA. The company…
(RTTNews) - AngioDynamics, Inc. (ANGO) reported a third quarter GAAP net loss of $8.1 million, or a loss per share of $0.19 compared to a loss of $4.4 million or $0.11 per share, last year. On a pro forma basis, net loss was $13.1 million…
* AngioDynamics press release [https://seekingalpha.com/pr/20460369-angiodynamics-reports-fiscal-year-2026-third-quarter-financial-results-sustained-double-digit] (ANGO [https://seekingalpha.com/symbol/ANGO]): Q3 Non-GAAP EPS of -$0.07 bea…
The S&P 500 Index ($SPX) (SPY) on Wednesday closed up +0.72%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.48%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +1.18%. June E-mini S&P futures (ESM26) rose +0.74%, and June E…
Major earnings expected before the bell on Thursday include: * Acuity (AYI [https://seekingalpha.com/symbol/AYI]) * Lindsay Corporation (LNN [https://seekingalpha.com/symbol/LNN]) * AngioDynamics (ANGO [https://seekingalpha.com/symbol/ANGO…
Quant rankings for the upcoming earnings calendar show strength concentrated in consumer discretionary and select industrial and health care names, while weakness is more pronounced across health care, technology, and parts of consumer-fac…
[Nest of Eggs] LindaJoHeilman As the calendar turns from March to April, a holiday-shortened week still delivers a diverse set of earnings with the potential to offer fresh directional cues. Consumer and brand momentum will be in focus wit…
AngioDynamics ANGO has been gaining from its solid prospects with NanoKnife and an increased focus on cancer treatment markets. The optimism, led by a solid first-quarter fiscal 2026 performance, positive ongoing studies and a broad produc…
Veeva Systems, Inc. VEEV reported adjusted earnings per share (EPS) of $2.06 for the fourth quarter of fiscal 2026, which increased 18.4% from the year-ago figure of $1.74. Adjusted EPS beat the Zacks Consensus Estimate by 7.3%. GAAP EPS i…